Johnson & Johnson (NYSE: JNJ) reported topline results from a Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder. The study successfully met its primary endpoint, demonstrating a statistically significant and rapid reduction in manic symptoms compared to placebo at Week 3, with improvements appearing as early as Day 3.
The trial evaluated a once-daily dose of 42mg Caplyta against placebo over a three-week duration in patients with manic episodes, with or without mixed features. Participants receiving Caplyta achieved a 4.8-point greater reduction in Young Mania Rating Scale total scores compared to placebo at Week 3. The benefits of the treatment were maintained from Day 3 onward.
Caplyta also delivered statistically significant improvements across key secondary measures. On the Clinical Global Impression–Severity scale, treated participants showed enhanced overall illness severity reductions compared to placebo. Additionally, 45.8% of patients taking Caplyta achieved a clinical response, defined as a 50% or greater reduction in symptom scores, versus 20.9% of placebo subjects.
The therapy demonstrated a favorable tolerability profile with low discontinuation rates, consistent with its established safety profile. A second pivotal Phase 3 study (Study 452) evaluating Caplyta for the treatment of manic episodes in adults with bipolar I disorder has been completed, and data analysis is underway.
At the time of publication, Johnson & Johnson shares were up 0.31% to $270.79.
